Long noncoding RNAs as regulators of pediatric acute myeloid leukemia

Neyazi, Sina; Ng, Michelle; Heckl, Dirk; Klusmann, Jan‐Henning

doi:10.1186/s40348-022-00142-2

Cited by 6 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a more clinically relevant scenario, UCA1 knockdown was shown to suppress the chemoresistance of pediatric AML by inhibiting glycolysis through direct binding with miR-125a (Zhang Y. et al, 2018). There are several examples of lncRNAs that have been characterized in pediatric AML that show correlations to patient prognosis and survival; such examples were summarized in a recent review by Neyazi et al (2022). In a recent comprehensive study, Vanhooren et al (2022) performed a miRNA-lncRNA network analysis in leukemic stem cells (LSCs) and leukemic blasts (L-blasts) from pediatric AML patients; this study identified several novel lncRNAs and miRNAs in pediatric AML that could become new biomarkers for risk stratification and targeted therapy in the future.…”

Section: Lncrnas In Pediatric Amlmentioning

confidence: 99%

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Dutta,

Akhade,

Choudhury

et al. 2024

Front. RNA Res.

View full text Add to dashboard Cite

Advancements and innovations in transcriptomics and computational biology have revealed long non-coding RNAs (lncRNAs) as some of the major regulators of essential biological processes. Their restricted spatial and temporal expressions as well as ability to interact with nucleic acids (DNA and RNA) and proteins make them key players in chromosome integrity, genomic architecture, and transcriptional and post-transcriptional regulation. Their dysregulation has been associated with numerous diseases and pathological conditions, including cancers. Myeloid leukemia is a malignancy of the hematopoietic system, and its pathobiology has been found to have increasing number of lncRNAs with functional significance. This comprehensive review summarizes a majority of the reported lncRNAs in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), focusing on the regulatory mechanisms by which they modulate the disease progression and pathogenesis, their potential as diagnostics and prognostic markers, and their feasibility as novel therapeutic targets. We also highlight our recent work on the significance of the lncRNA Hmrhl in CML, which has been found to regulate gene transcription at the chromatin level.

show abstract

Section: Lncrnas In Pediatric Amlmentioning

confidence: 99%

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Dutta,

Akhade,

Choudhury

et al. 2024

Front. RNA Res.

View full text Add to dashboard Cite

show abstract

“…Dysregulation of lncRNAs (such as lncRNA CRNDE, KCNQ1OT1, and ZFAS1) is implicated in chemoresistance in AML [10][11][12][13]. Long intergenic non coding RNAs (lincRNAs), a type of lncRNA, are emerging as key regulators in cancer development.…”

Section: Introductionmentioning

confidence: 99%

Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis

Liu,

Zhu,

Liao

et al. 2024

Biol Direct

View full text Add to dashboard Cite

Background Most patients with acute myeloid leukemia (AML) eventually develop drug resistance, leading to a poor prognosis. Dysregulated long gene non coding RNAs (lincRNAs) have been implicated in chemoresistance in AML. Unfortunately, the effects of lincRNAs which participate in regulating the Adriamycin (ADR) resistance in AML cells remain unclear. Thus, the purpose of this study is to determine LINC00987 function in ADR-resistant AML. Methods In this study, ADR-resistant cells were constructed. LINC00987, miRNAs, and HMGA2 mRNA expression were measured by qRT-PCR. P-GP, BCRP, and HMGA2 protein were measured by Western blot. The proliferation was analyzed by MTS and calculated IC50. Soft agar colony formation assay and TUNEL staining were used to analyze cell colony formation and apoptosis. Xenograft tumor experiment was used to analyze the xenograft tumor growth of ADR-resistant AML. Results We found that higher expression of LINC00987 was observed in AML patients and associated with poor overall survival in AML patients. LINC00987 expression was increased in ADR-resistant AML cells, including ADR/MOLM13 and ADR/HL-60 cells. LINC00987 downregulation reduces ADR resistance in ADR/MOLM13 and ADR/HL-60 cells in vitro and in vivo, while LINC00987 overexpression enhanced ADR resistance in MOLM13 and HL-60 cells. Additionally, LINC00987 functions as a competing endogenous RNA for miR-4458 to affect ADR resistance in ADR/MOLM13 and ADR/HL-60 cells. HMGA2 is a target of miR-4458. LINC00987 knockdown and miR-4458 overexpression reduced HMGA2 expression. HMGA2 overexpression enhanced ADR resistance, which reversed the function of LINC00987 silencing in suppressing ADR resistance of ADR/MOLM13 and ADR/HL-60 cells. Conclusions Downregulation of LINC00987 weakens ADR resistance by releasing miR-4458 to deplete HMGA2 in ADR/MOLM13 and ADR/HL-60. Therefore, LINC00987 may act as the therapeutic target for treating chemoresistant AML.

show abstract

“…While the molecular mechanisms of action for greater than 95% of lncRNAs are not clear to date, an increasing number of studies are identifying lncRNAs that have critical roles in cancer, including AML (Mishra et al, 2022 ). Over the last 3 years, other reviews have discussed the role of noncoding RNAs in hematological malignancies, however, they have focused on other noncoding RNA species such as microRNAs and circRNAs or have looked at lncRNAs in a pediatric setting (Bhattacharya & Gutti, 2022 ; Y. Liu et al, 2019 ; Neyazi et al, 2022 ). In this review, we analyze recent findings in the field of lncRNAs in AML with a focus on the specific mechanisms of lncRNAs in AML such as driving proliferation, differentiation block, therapy resistance as well as their function as tumor suppressors and utility as AML biomarkers.…”

Section: Introductionmentioning

confidence: 99%

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

Connerty

Lock

2023

WIREs RNA

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are traditionally defined as RNA transcripts longer than 200 nucleotides that have no protein coding potential. LncRNAs have been identified to be dysregulated in various types of cancer, including the deadly hematopoietic cancer—acute myeloid leukemia (AML). Currently, survival rates for AML have reached a plateau necessitating new therapeutic targets and biomarkers to improve treatment options and survival from the disease. Therefore, the identification of lncRNAs as novel biomarkers and therapeutic targets for AML has major benefits. In this review, we assess the key studies which have recently identified lncRNAs as important molecules in AML and summarize the current knowledge of lncRNAs in AML. We delve into examples of the specific roles of lncRNA action in AML such as driving proliferation, differentiation block and therapy resistance as well as their function as tumor suppressors and utility as biomarkers.This article is categorized under: RNA in Disease and Development > RNA in Disease

show abstract

Long noncoding RNAs as regulators of pediatric acute myeloid leukemia

Cited by 6 publications

References 91 publications

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Long non-coding RNAs: emerging functional players in the pathobiology and progression of myeloid leukemia

Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis

The tip of the iceberg—The roles of long noncoding RNAs in acute myeloid leukemia

Contact Info

Product

Resources

About